Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise-Reference-Cited by-同舟云学术

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

Published:2018-02 Issue:4 Volume:83 Page:311-319
ISSN:0006-3223
Container-title:Biological Psychiatry
language:en
Short-container-title:Biological Psychiatry

Author:

van Dyck Christopher H.

Publisher

Elsevier BV

Subject

Biological Psychiatry

Reference66 articles.

1. The amyloid hypothesis of Alzheimer’s disease at 25 years;Selkoe;EMBO Mol Med,2016

2. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial;Gilman;Neurology,2005

3. Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer’s disease: Results from two phase 2 studies;Arai;Curr Alzheimer Res,2015

4. Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer’s disease;Pasquier;J Alzheimer Dis,2016

5. Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early Alzheimer’s disease: Amyloid imaging positron emission tomography and safety results from a phase 2 study;van Dyck;J Prev Alzheimers Dis,2016

Cited by 424 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer’s disease mouse model;Brain, Behavior, and Immunity;2024-11

2. Degradation of Amyloid-β Species by Multi-Copper Oxidases;Journal of Alzheimer's Disease;2024-09-10

3. A comprehensive review of advanced focused ultrasound (FUS) microbubbles-mediated treatment of Alzheimer's disease;Heliyon;2024-09

4. A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD);Bioorganic & Medicinal Chemistry;2024-09

5. Aggregation Mechanisms and Molecular Structures of Amyloid‐β in Alzheimer's Disease;Chemistry – A European Journal;2024-08-02